BioCentury | Dec 3, 2020
Deals

Artios picks Germany’s Merck for first major pharma collaboration in synthetic lethality

Artios’ deal with German pharma Merck represents the latest vote of confidence in the DNA damage repair sector, and extends the privately held biotech’s cash runway as it prepares for its first clinical trials. For its...
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the...
BioCentury | Sep 10, 2020
Finance

MiNA raises £23M in first venture round 12 years after launch

After financing itself for 12 years via high-net-worth individuals and Sosei, London-based MiNA has tapped a traditional VC to lead its series A round to expand its pipeline of small activating RNA therapeutics.  MiNA Therapeutics Ltd....
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

NextCure Inc. (NASDAQ:NXTC) said CMO Kevin Heller has resigned, effective Aug. 4, to pursue a new opportunity; the immunotherapy company is searching for a successor. NextCure also said Monday that, based on response data, it...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

Fourteen months after leading biochemist Carolyn Bertozzi published a preprint on a new class of compounds that degrade extracellular proteins inaccessible to PROTACs, Versant-built Lycia has emerged with $50 million to turn that technology into...
BioCentury | May 26, 2020
Finance

insitro to translate $143 million B round into drug discovery platform

AI and machine learning company insitro is looking to drug discovery as its next phase of platform development with an Andreessen Horowitz-led $143 million series B round. The company has spent the two years since...
BioCentury | May 14, 2020
Deals

With Northern Biologics deal, Boehringer adds pair of hot topics to its immuno-oncology basket

...Versant, was acquired by Bayer AG (Xetra:BAYN) for $240 million up front. In 2018, Versant’s Inception 4...
BioCentury | May 14, 2020
Regulation

Manufacturing limits spark fears of COVID-19 vaccine nationalism

There is broad agreement on the importance of creating policies to determine which countries will receive COVID-19 vaccines, but little concurrence on what those policies should be or how they will be created. On Wednesday,...
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

Ventus emerged from stealth on Wednesday with a Versant-led $60 million series A round and a drug discovery platform designed to tackle one of the biggest challenges of targeting innate immune signaling: the lack of...
Items per page:
1 - 10 of 485
BioCentury | Dec 3, 2020
Deals

Artios picks Germany’s Merck for first major pharma collaboration in synthetic lethality

Artios’ deal with German pharma Merck represents the latest vote of confidence in the DNA damage repair sector, and extends the privately held biotech’s cash runway as it prepares for its first clinical trials. For its...
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the...
BioCentury | Sep 10, 2020
Finance

MiNA raises £23M in first venture round 12 years after launch

After financing itself for 12 years via high-net-worth individuals and Sosei, London-based MiNA has tapped a traditional VC to lead its series A round to expand its pipeline of small activating RNA therapeutics.  MiNA Therapeutics Ltd....
BioCentury | Jul 16, 2020
Management Tracks

NextCure CMO Heller to resign; plus Vertex, Turning Point, Scholar Rock, C4, Vor and more

NextCure Inc. (NASDAQ:NXTC) said CMO Kevin Heller has resigned, effective Aug. 4, to pursue a new opportunity; the immunotherapy company is searching for a successor. NextCure also said Monday that, based on response data, it...
BioCentury | Jun 10, 2020
Emerging Company Profile

Autobahn: fine-tuning thyroid agonism to remyelinate axons

Autobahn, which launched with a $76 million series B Tuesday, joins at least six other companies with disclosed remyelination programs for multiple sclerosis. But the biotech thinks its prodrug, slated to enter the clinic next...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

Fourteen months after leading biochemist Carolyn Bertozzi published a preprint on a new class of compounds that degrade extracellular proteins inaccessible to PROTACs, Versant-built Lycia has emerged with $50 million to turn that technology into...
BioCentury | May 26, 2020
Finance

insitro to translate $143 million B round into drug discovery platform

AI and machine learning company insitro is looking to drug discovery as its next phase of platform development with an Andreessen Horowitz-led $143 million series B round. The company has spent the two years since...
BioCentury | May 14, 2020
Deals

With Northern Biologics deal, Boehringer adds pair of hot topics to its immuno-oncology basket

...Versant, was acquired by Bayer AG (Xetra:BAYN) for $240 million up front. In 2018, Versant’s Inception 4...
BioCentury | May 14, 2020
Regulation

Manufacturing limits spark fears of COVID-19 vaccine nationalism

There is broad agreement on the importance of creating policies to determine which countries will receive COVID-19 vaccines, but little concurrence on what those policies should be or how they will be created. On Wednesday,...
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

Ventus emerged from stealth on Wednesday with a Versant-led $60 million series A round and a drug discovery platform designed to tackle one of the biggest challenges of targeting innate immune signaling: the lack of...
Items per page:
1 - 10 of 485